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Diabetes is associated with numerous complications, such as diabetic skin wounds or
ulcerations. The aim of this study was to evaluate experimentally the effectiveness
of applying polycaprolactone (PCL)‐gelatin scaffold, with or without rat CD93
hematopoietic stem cells (HSCs), in diabetic wound healing in a rat model. CD93
HSCs were aseptically isolated from rat bone marrow using fluorescent activated cell
sorting (FACS) method and FACS‐SORTER. A total of 25 Wistar rats were divided
into five groups including Group I (sham, nondiabetic, and wound covered only with
sterile dressing), II (control, diabetic rat), III (CD93 HSCs alone), IV (PCL‐gelatin
scaffold), and V (CD93 HSCs+PCL‐gelatin scaffold). Animals were killed on Days 7,
14, or 28 posttreatment and histological sections were blindly evaluated by two
expert pathologists. Death‐associated protein kinase 1 (DAPK‐1) gene and vesicular
endothelial growth factors (VEGF) protein expression were evaluated using reverse
transcription‐polymerase chain reaction and western blot, respectively. The thickest
and the thinnest epidermises microscopically were belonged to CD93+HSCs+scaffold
and the control group, respectively. The growth rate of the epidermis and adnexal
epithelia was the highest in both the cell and cell+scaffold groups. Evaluation of the
protein expression level of VEGF indicated that the expression levels of this growth
factor were the most on Day 7 posttreatment in sham, HSCs alone, and HSCs cell
+scaffold groups. While the lowest expression levels of this growth factor was
detected in the control and scaffold groups. The gene expression level of DAPK‐1 on
Day 7 posttreatment was higher than that of the Day 14 posttreatment in all groups.
The highest and lowest gene expression levels of DAPK‐1 belonged to control and
sham groups, respectively. According to our findings, CD93 HSCs offer new prospects
for the treatment of diabetic ulcers and concomitant application of these cells with
PCL‐gelatin nanofiber scaffold significantly improves diabetic wound treatment.
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1 | INTRODUCTION
Diabetes is the most common endocrine disorder and the most
important metabolic disease in human. It is predicted that the
number of people with diabetes will reach 300 million cases
worldwide by 2030 (Wild, Roglic, Green, Sicree, & King, 2004).
Diabetes is associated with numerous complications, such as
peripheral neuropathy, stroke, cardiovascular disease, chronic renal
